Factors of poor prognosis for new coronavirus infection in patients with cardiovacular pathology

L. Eliseeva, N. Borovkova, P. S. Zubeev, G. Zubeeva, E. S. Yumanova
{"title":"Factors of poor prognosis for new coronavirus infection in patients with cardiovacular pathology","authors":"L. Eliseeva, N. Borovkova, P. S. Zubeev, G. Zubeeva, E. S. Yumanova","doi":"10.30629/0023-2149-2023-101-12-637-642","DOIUrl":null,"url":null,"abstract":"Aim. To assess the structure of cardiovascular pathology in patients with new coronavirus infection (NCI), to identify factors of poor prognosis in these individuals. Material and methods. The study was conducted on the basis of the COVID-19 infectious diseases hospital of the City Hospital No. 33 of Nizhny Novgorod. The study included 284 patients after applying inclusion and exclusion criteria. All subjects were divided into groups: the main group (n = 207) — patients with NCI and cardiovascular diseases (CVD), as well as comorbid diseases, the comparison group (n = 24) with NCI and CVD, the control group (n = 53) with NCI without any comorbid diseases. Demographic indicators, BMI, laboratory parameters, comorbidity and therapy were analyzed. Results. During the study, it was revealed that the most severe course of COVID-19 is characteristic of the main group, and only among them there were fatal outcomes (25% of cases). Analyzing the prevalence of CVD, it turned out that arterial hypertension was the most common in the main group and in the comparison group, coronary heart disease and heart failure were registered somewhat less frequently. The development of acute cardiovascular accidents occurred only in the main group. A mathematical model was developed to determine the risk of death in patients with NCI who are in the hospital. This model is statistically significant (p < 0.001). Conclusion. The older age of patients, the development of acute myocardial infarction, first identified atrial fibrillation and a decrease in saturation contributed to an increased risk of mortality in patients with NCI and CVD. Among drug therapy, the administration of favipiravir, tocilizumab and statins had a beneficial effect on the outcome of diseases.","PeriodicalId":10439,"journal":{"name":"Clinical Medicine (Russian Journal)","volume":"60 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine (Russian Journal)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30629/0023-2149-2023-101-12-637-642","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aim. To assess the structure of cardiovascular pathology in patients with new coronavirus infection (NCI), to identify factors of poor prognosis in these individuals. Material and methods. The study was conducted on the basis of the COVID-19 infectious diseases hospital of the City Hospital No. 33 of Nizhny Novgorod. The study included 284 patients after applying inclusion and exclusion criteria. All subjects were divided into groups: the main group (n = 207) — patients with NCI and cardiovascular diseases (CVD), as well as comorbid diseases, the comparison group (n = 24) with NCI and CVD, the control group (n = 53) with NCI without any comorbid diseases. Demographic indicators, BMI, laboratory parameters, comorbidity and therapy were analyzed. Results. During the study, it was revealed that the most severe course of COVID-19 is characteristic of the main group, and only among them there were fatal outcomes (25% of cases). Analyzing the prevalence of CVD, it turned out that arterial hypertension was the most common in the main group and in the comparison group, coronary heart disease and heart failure were registered somewhat less frequently. The development of acute cardiovascular accidents occurred only in the main group. A mathematical model was developed to determine the risk of death in patients with NCI who are in the hospital. This model is statistically significant (p < 0.001). Conclusion. The older age of patients, the development of acute myocardial infarction, first identified atrial fibrillation and a decrease in saturation contributed to an increased risk of mortality in patients with NCI and CVD. Among drug therapy, the administration of favipiravir, tocilizumab and statins had a beneficial effect on the outcome of diseases.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心血管病患者新感染冠状病毒的不良预后因素
目的评估新冠状病毒感染(NCI)患者心血管病变的结构,确定这些患者预后不良的因素。材料和方法。研究在下诺夫哥罗德市第 33 医院 COVID-19 传染病医院的基础上进行。根据纳入和排除标准,研究共纳入 284 名患者。所有受试者被分为几组:主要组(n = 207)--NCI 和心血管疾病(CVD)以及合并症患者;对比组(n = 24)--NCI 和 CVD 患者;对照组(n = 53)--NCI 无合并症患者。对人口统计学指标、体重指数、实验室参数、合并症和治疗进行了分析。结果显示研究显示,COVID-19 最严重的病程是主要群体的特征,其中只有 25% 的病例出现致命结果。在分析心血管疾病的发病率时发现,动脉高血压在主要群体中最为常见,而在对比群体中,冠心病和心力衰竭的发病率略低。急性心血管意外仅发生在主要群体中。我们建立了一个数学模型,以确定住院的全国心脏病患者的死亡风险。该模型具有统计学意义(p < 0.001)。结论患者年龄偏大、发生急性心肌梗死、首次发现心房颤动以及饱和度下降,都会增加 NCI 和心血管疾病患者的死亡风险。在药物治疗中,服用法非比拉韦、托珠单抗和他汀类药物对疾病的治疗效果有利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Maksimov and the development of the theory of hematopoiesis ( on the 150th anniversary of his birth) Problems of diagnosis and treatment of Connshing syndrome In memory of Valery Grigorievich Demikhov Diagnosis and treatment of acute appendicitis in patients with the new coronavirus infection COVID-19 Tuberous sclerosis. Clinical observation of a 10-year-old girl
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1